BeOne Medicines director sells 31,027 depositary shares
The director's ADS sales were made under a Rule 10b5-1 trading plan adopted on June 9, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BeOne Medicines Ltd. director Xiaodong Wang, Chair of the Scientific Advisory Board, exercised options covering 403,351 ordinary shares at an exercise price of $2.84 per ordinary share on October 13, 2026, and acquired 31,027 ADS. He sold 31,027 ADS that day under a Rule 10b5-1 trading plan adopted June 9, 2026. Each ADS represents 13 ordinary shares. Direct ordinary-share holdings afterward were 4,588,113, and the option position was reported at 403,364 shares following the transaction.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
11 txns
Insider
Wang Xiaodong
Role
Director
Sold
31,027 shs ($10.89M)
Approx. gross sale proceeds
$10.89M
Approx. exercise cost
$1.15M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option (Right to Buy) F11, F12 | 403,351 | $0.00 | $0.00 |
| Exercise | American Depositary Shares F4 | 31,027 | $36.90 | $1.14M |
| Sale | American Depositary Shares F4, F5, F6 | 7,167 | $349.5613 | $2.51M |
| Sale | American Depositary Shares F4, F5, F7 | 10,361 | $350.4741 | $3.63M |
| Sale | American Depositary Shares F4, F5, F8 | 5,681 | $351.3958 | $2.00M |
| Sale | American Depositary Shares F4, F5, F9 | 6,558 | $352.5691 | $2.31M |
| Sale | American Depositary Shares F4, F5, F10 | 1,260 | $353.2367 | $445K |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares F1 | -- | -- | -- |
| holding | Ordinary Shares F2 | -- | -- | -- |
| holding | Ordinary Shares F3 | -- | -- | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 403,364 contracts (Direct);
American Depositary Shares — 0 shares (Direct);
Ordinary Shares — 4,588,113 shares (Direct);
Ordinary Shares — 4,978,213 shares (Indirect, See Footnote)
Footnotes (12)
- F1. These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership.
- F2. These securities are held by Wang Investment LLC, of which 99% of the limited liability company interests are owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.
- F3. These securities are held by the spouse of the Reporting Person.
- F4. Each American Depositary Share represents 13 Ordinary Shares.
- F5. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.98 to $349.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $349.98 to $350.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.98 to $351.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.99 to $352.95, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.01 to $353.325, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- F11. The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.
- F12. These securities vest over a four-year period as follows: 25% on July 13, 2017, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.
Key Figures
Ordinary shares underlying options exercised: 403,351 ordinary shares
Option exercise price: $2.84 per ordinary share
ADS acquired: 31,027 ADS
+3 more
6 metrics
Ordinary shares underlying options exercised
403,351 ordinary shares
October 13, 2026
Option exercise price
$2.84 per ordinary share
Options exercised October 13, 2026
ADS acquired
31,027 ADS
October 13, 2026
ADS sold
31,027 ADS
October 13, 2026
Direct ordinary shares following transactions
4,588,113 ordinary shares
Reported after the October 13, 2026 transactions
Shares in reported option position following transaction
403,364 ordinary shares
Reported after the October 13, 2026 transaction
Key Terms
American Depositary Share, Rule 10b5-1 trading plan, weighted average price
3 terms
Rule 10b5-1 trading plan regulatory
"The sale was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many ONC ADS did Xiaodong Wang sell, and at what prices?
Xiaodong Wang sold 31,027 ADS on October 13, 2026, in five groups at weighted-average prices of $349.5613 for 7,167 ADS, $350.4741 for 10,361, $351.3958 for 5,681, $352.5691 for 6,558, and $353.2367 for 1,260 ADS. The sales were made under a Rule 10b5-1 trading plan adopted June 9, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
